ArticleBrain & spine2026
Multiple myeloma with spinal involvement: Renal dysfunction and albuminuria are associated with progressive sarcopenia in a longitudinal CT morphometric study.
Article in Brain & spine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Kidney dysfunction is a frequent complication of multiple myeloma (MM). However, its associations with sarcopenia and visceral adipose tissue loss, emerging prognostic markers of frailty, remain insufficiently characterized in MM. Computed tomography (CT)-based morphometry provides an objective and reproducible assessment of body composition. Albuminuria, an established marker of kidney damage, is often underrecognized outside nephrology despite its potential relevance for disease burden and physical decline. Methods: We retrospectively analyzed 86 MM patients (2009-2024) with three sequential whole-body CT scans. CT morphometry included skeletal muscle index (SMI), paraspinal muscle index (PSMI), psoas muscle index (PMI), skeletal muscle density (SMD), and visceral adipose tissue (VAT). Kidney function (serum creatinine, eGFR, albuminuria) and serum albumin were assessed in relation to longitudinal changes in body composition and clinical outcomes, including Eastern Cooperative Oncology Group (ECOG) performance status, pain severity (VAS), and World Health Organization (WHO) analgesic use. Results: Both impaired baseline kidney function (eGFR <60 mL/min) and progressive eGFR decline (≥25 %) were associated with significantly accelerated loss of skeletal and visceral muscle parameters. Notably, patients with stable but impaired baseline kidney function also exhibited greater muscle and fat loss compared with those with preserved and stable renal function. Albuminuria >30 mg/24 h was also associated with adverse CT morphometry, irrespective of eGFR. In addition, baseline hypoalbuminemia (<3.5 g/dL) and longitudinal serum albumin declines ≥10 % correlated with unfavorable CT-morphometric trajectories. Functionally, progressive kidney dysfunction was associated with worsening ECOG performance status. Conclusions: Kidney dysfunction was independently associated with muscle and adipose tissue loss in MM patients. In addition, albuminuria represents an additional, underrecognized marker of progressive sarcopenia, even independent of eGFR. These findings underscore the importance of integrating renal parameters and sequential imaging-based assessments for risk stratification and supportive care planning in patients with MM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.